Bioanalysis Zone’s Post

Check out this webinar, which is happening tomorrow in the Bioanalysis Zone. Pharmaron is proud to support this webinar on "The origin-adjusted approach for biomarker quantification by LC–MS". Learn how this approach can enhance your biomarker workflows. https://lnkd.in/d28Jpfrq

Don't miss out—tomorrow we go live with our webinar on *The origin-adjusted approach for biomarker quantification by LC–MS*! This is your chance to learn how this approach can enhance your biomarker workflows. Last chance to register! >>> https://hubs.ly/Q02XW3gV0

☀️ Our team is in San Diego today for the #BiomarkersUS24 conference! 🧬 Want to find out how to strengthen your biomarker research? Drop by Booth 9 to chat to our team and find out how we support biomarker development from discovery right through to clinical phases. Book a meeting today! 👉 https://bit.ly/3HQzLHL #Biomarkers #PrecisionMedicine

Quanterix is pleased to collaborate with Tharick Pascoal and his team at the University of Pittsburgh on the CliPAD project, enabling groundbreaking developments in Alzheimer's diagnostics.

"Why did ELISA bring MSD-ECL to the party? Because ELISA can find a protein, but MSD-ECL lights up the room with electrochemiluminescence—literally! Together, they're the ultimate immune-response detectives, solving biomarker mysteries faster than your Wi-Fi on a good day. 🧪✨ 💡 Did you know? ELISA (Enzyme-Linked Immunosorbent Assay) is a tried-and-true method for detecting and quantifying proteins in samples. MSD-ECL (Meso Scale Discovery Electrochemiluminescence) takes it up a notch by producing light-based signals that are even more sensitive and reliable. 🤔 Question of the day: If ELISA is the Sherlock Holmes of immunoassays, what would you call MSD-ECL? Drop your creative answers below! #LabJokes #ScienceHumor #ELISA #MSDECL #Immunoassays #Diagnostics

Only a few days left to register for our live webinar, "What is a Good Biomarker?" As protein biomarkers become central to precision medicine, there is a clear need for defining a robust and efficient development pipeline. Join us to explore key challenges and opportunities in streamlining biomarker discovery, including: - Ensuring accurate protein measurements that capture true biological signals during assay development. - Applying statistical analysis to detect meaningful differences and generate actionable insights - Utilizing scalable methods across all stages of biomarker development. Reserve your spot https://hubs.la/Q02Yb3pm0

Are HIT immunoassays truly "positive" or "negative"? 🩸 Not so simple! Using data from 1,393 patients in the TORADI-HIT study, this study reveal diagnostic value across the entire dynamic range of H/PF4 assays (CLIA & ELISA). 📊 🔍 Key findings: LR ≥ 10 at 0.4 U/ml (CLIA) vs 0.64 OD (ELISA). LR ≥ 100 at 12 U/ml (CLIA) vs 3.0 OD (ELISA). 🧮Post-test probabilities for individual patients can be estimated using a web-based calculator https://lnkd.in/g5eZG6Fg Henning Nilius | Samra Naas | Jan-Dirk Studt | Dimitrios, Tsakiris | Andreas Greinacher | Mendez Adriana | Adrian Schmidt | Walter Wuillemin | Bernhard Gerber | Prakash Vishnu | Lukas Graf | Johanna Kremer Hovinga | Tamam Bakchoul | Christos Nakas | Michael Nagler

I’m pleased to share that our latest research has been published in the Journal of Thrombosis and Hemostasis. This study investigates how the likelihood of heparin-induced thrombocytopenia (HIT) changes with numerical test results of anti-heparin/pf4 immunoassays, aiming to move beyond the binary interpretations. By focusing on the full dynamic range, we hope this work contributes to more precise decision-making in HIT. I’m grateful to my supervisor (Michael Nagler) and our collaborators for making this possible. The full article is available here: https://lnkd.in/e3hdBSRq https://lnkd.in/ekd-xncf

How can we effectively address interfering factors in multiplex immunoassays? Discover the answer and dive into the rest of the thought-provoking Q&A session of our webinar "What is a good biomarker?", where we explored: - Challenges and opportunities in developing assays that capture true biological signals in protein measurements. - Statistical analysis considerations to detect meaningful differences and generate actionable insights. - The power of utilizing scalable methods to streamline biomarker development. View on-demand now https://hubs.la/Q02_V7Sz0

Model based meta-analysis (#MBMA) is one of the most impactful tools in our #pharmacometrics toolkit. (Yes, I will continue to beat that drum🥁) Are you going to #PAGE2024 and do you want to know more about MBMA? Come and visit the three posters of innovative work we have done in collaboration with #MSD, and stop by booth 23&24 for more information!